Drawing for TRINITY

USPTO serial 98498390

TRINITY

Reviewed by CopyMark Law Group

Status 688Notice of Allowance
Filing date
Status date
Registration date
—
Examiner
THOMA, GABRIELLE M
Law office
INTENT TO USE SECTION

What this means

The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.

Status 688: Status 688 means a Notice of Allowance was issued. For intent-to-use applications, you must file a Statement of Use with specimens or request an extension before the deadline — usually six months from the notice date.

Need help with TRINITY?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $1,095*

Plus Government fees of $625

Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Samantha C. Markley

Samantha C. Markley LOZA & LOZA, LLP305 N. Second Ave., #127Upland, CA 91786United States

Goods and services

ClassDescriptionStatusFirst use
001Assays and reagents for use in genetic research; diagnostic reagents for scientific or research use; diagnostic reagents for clinical or medical laboratory use, other than for medical or veterinary purposes; reagents and reagent kits, other than for medical or veterinary purposes, comprised primarily of nucleic acids, naturally occurring or modified nucleotides, enzymes, labels, and buffers, all for the purpose of preparing, detecting, sequencing, and analyzing nucleic acids and other biological molecules, samples of biological molecules, genes, genomes, nucleotide sequence variants and modifications, regulation, transcription, and expression for scientific research use, for diagnostic scientific use, and for clinical laboratory research use; clinical diagnostic reagents for laboratory use, other than for medical or veterinary purposes; reagent kits and reagent beads, other than for medical or veterinary purposes, with attached biomolecules, comprised primarily of oligonucleotides and other nucleic acids, natural and modified nucleotides, polypeptides, buffers, labels, and substrates, for clinical diagnostic laboratory purposesACTIVE—
005Medical diagnostic reagents; clinical medical diagnostic reagents; reagent kits and reagent beads with attached biomolecules, comprised primarily of oligonucleotides and other nucleic acids, natural and modified nucleotides, polypeptides, buffers, labels, and substrates, for clinical medical diagnostic purposes; reagents and reagent kits comprised primarily of nucleic acids, naturally occurring or modified nucleotides, enzymes, labels, and buffers, all for the purpose of preparing, detecting, sequencing, and analyzing nucleic acids and other biological molecules, samples of biological molecules, genes, genomes, nucleotide sequence variants and modifications, regulation, transcription, and expression for diagnostic medical use and for clinical medical use; diagnostic reagents for clinical or medical laboratory use, for medical or veterinary purposes; reagents and reagent kits, for medical or veterinary purposes, comprised primarily of nucleic acids, naturally occurring or modified nucleotides, enzymes, labels, and buffers, all for the purpose of preparing, detecting, sequencing, and analyzing nucleic acids and other biological molecules, samples of biological molecules, genes, genomes, nucleotide sequence variants and modifications, regulation, transcription, and expression for clinical laboratory research use; clinical diagnostic reagents for laboratory use, for medical or veterinary purposes; reagent kits and reagent beads, for medical or veterinary purposes, with attached biomolecules, comprised primarily of oligonucleotides and other nucleic acids, natural and modified nucleotides, polypeptides, buffers, labels, and substrates, for clinical diagnostic laboratory purposesACTIVE—
009Computer systems, namely, computer hardware, downloadable and recorded computer software and associated downloadable data files for collecting, storing, analyzing and reporting biological information, and for sample tracking and managing projects, laboratory workflow and data, all the foregoing for use in the fields of diagnostic and clinical research and for clinical diagnostic purposes; downloadable and recorded computer software for data collection, management, and analysis of genetic information for use in the fields of diagnostic and clinical research and for clinical diagnostic purposes; clinical diagnostic instruments for scientific use, namely, nucleic acid sequencers, imaging devices for nucleic acids and biological molecules and analyzers in the nature of scientific laboratory research instruments for DNA analysisACTIVE—
010Clinical diagnostic instruments for medical use, namely, nucleic acid sequencers, imaging devices for biomolecules and analyzers in the nature of flow-based analyzers providing cell and particle analysis, detection, or countingACTIVE—
042Providing reagent sample diagnostic testing services for others for scientific research purposes and scientific research related thereto; clinical diagnostic services for scientific research purposes, namely, preparing, amplifying, labeling, detecting, analyzing and sequencing nucleic acids from human beings; providing online non-downloadable computer software for collecting, storing, analyzing and reporting biological information, and for sample tracking and managing projects, laboratory workflow and data, all the foregoing for use in the fields of diagnostic and clinical research and for clinical diagnostic purposes; providing online non-downloadable computer software for data collection, management, and analysis of genetic information for use in the fields of diagnostic and clinical research and for clinical diagnostic purposesACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (NOAM): A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.

DateCodeEventWhat it means
May 5, 2026NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Mar 10, 2026NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Mar 10, 2026PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Mar 4, 2026NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Feb 12, 2026CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Feb 9, 2026TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Feb 9, 2026CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Feb 9, 2026ALIEASSIGNED TO LIE—
Feb 2, 2026ERSITEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED—
Oct 2, 2025GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
Oct 2, 2025GNSLLETTER OF SUSPENSION E-MAILED—
Oct 2, 2025CNSLSUSPENSION LETTER WRITTEN—
Aug 14, 2025TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Aug 14, 2025CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Aug 14, 2025ERFRTEAS REQUEST FOR RECONSIDERATION RECEIVED—
May 7, 2025XELGAPPLICATION EXTENSION GRANTED/RECEIPT PROVIDED—
May 7, 2025XELRAPPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED—
Feb 19, 2025GNFNNOTIFICATION OF FINAL REFUSAL EMAILED—
Feb 19, 2025GNFRFINAL REFUSAL E-MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Feb 19, 2025CNFRFINAL REFUSAL WRITTENA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Jan 29, 2025TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jan 29, 2025CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jan 29, 2025TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Oct 31, 2024GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Oct 31, 2024GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Oct 31, 2024CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Oct 28, 2024DOCKASSIGNED TO EXAMINER—
Sep 25, 2024NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Apr 12, 2024NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance